To Test or Not To Test – Avoiding Costly Planning Mistakes with Effective Dx Financial Pre-Launch Planning | Diaceutics

To Test or Not To Test – Avoiding Costly Planning Mistakes with Effective Dx Financial Pre-Launch Planning

May 26th, 2016

Peter Keeling
Mark Reis
Sanna Jousi

Are you at the pre-launch or commercial implementation stage of planning for a therapy and diagnostic? This webinar provides insights on how to optimize your therapy launch to maximize the therapy’s revenue opportunity.

Listen to the webinar to learn:

  • About effective financial planning for integrating diagnostics into your targeted therapy commercial strategy; and
  • That through optimization of the diagnostic, pharma can predict the revenue and patient share losses and gains that can be made in key markets and maximize the return on investment for the therapy asset.

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports


May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
September 11th, 2018
BRAF mutation testing in melanoma – Poster presented at European Congress of Pathology 2018
BRAF mutation testing in melanoma: a study including Austria, Germany and UK, highlighting concordance for current technologies, and potential requirement of more sensitive technologies in future applications.
View all publications